title: Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia.
abstract: We evaluated serum thyroid hormone and thyroid antibody levels, the serum TSH response to TRH, and the circadian pattern of serum TSH in 10 children and adolescents after radiation therapy for acute lymphoblastic leukemia. Four patients had received central nervous system preventive cranial irradiation and intrathecal chemotherapy, and the remaining 6 patients were treated with craniospinal irradiation for central nervous system relapse. Serum total T4 and T3 concentrations were within the normal range and thyroid antibodies were negative in all patients. Four patients who had received craniospinal irradiation had low free T4 levels. Prior to TRH administration, the overall mean serum TSH concentration was 5.4 +/- 1.3 mU/l, and the mean peak response to TRH was 33 +/- 6.5 mU/l. Both were significantly increased when compared to the levels observed in our control population (p less than 0.05 and less than 0.025, respectively). The overall mean nadir diurnal TSH was 3.6 +/- 0.8 mU/l, and the mean peak nocturnal TSH was 6.9 +/- 1.3 mU/l, both significantly elevated when compared to normal children (p less than 0.025). The mean nocturnal TSH surge, however, was not significantly different from normal. Four of 6 children treated with craniospinal irradiation, and one of four children treated with cranial irradiation had increased basal and peak serum TSH concentrations in response to TRH. One of the patients treated with cranial irradiation had an abnormal nocturnal TSH surge. We conclude that subtle primary hypothyroidism is relatively common in patients with acute lymphoblastic leukemia, particularly in those who have been treated with craniospinal irradiation.
authors.affiliation: Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
authors.forename: T
authors.initials: T
authors.lastname: Pasqualini
authors.forename: J
authors.initials: J
authors.lastname: McCalla
authors.forename: S
authors.initials: S
authors.lastname: Berg
authors.forename: D G
authors.initials: DG
authors.lastname: Poplack
authors.forename: S R
authors.initials: SR
authors.lastname: Rose
authors.forename: B C
authors.initials: BC
authors.lastname: Nisula
authors.forename: F
authors.initials: F
authors.lastname: Cassorla
mesh_terms: D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000097:blood / Q000276:immunology; D002648:Child; D002940:Circadian Rhythm / Q000502:physiology; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000503:physiopathology / Q000532:radiotherapy; D013131:Spine / Q000528:radiation effects; D013963:Thyroid Hormones / Q000097:blood / Q000276:immunology; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000502:physiology
chemical_list: D000906:Antibodies; D013963:Thyroid Hormones; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin